ライフサイエンスコーパス: malignant tumor

1 patients with extracranial progressive solid malignant tumors .

2 section of a pancreatic, hepatic, or gastric malignant tumor.

3 ification if their biopsy results revealed a malignant tumor.

4 Sebaceous cell carcinoma of the eyelid is a malignant tumor.

5 a is a life-threatening complication of this malignant tumor.

6 om a precancerous or preinvasive lesion to a malignant tumor.

7 herapeutic agents for the management of this malignant tumor.

8 dentification of subjects with a preclinical malignant tumor.

9 cancer remains the most lethal gynecological malignant tumor.

10 is generally considered a characteristic of malignant tumors.

11 potential therapeutic target for intestinal malignant tumors.

12 m, liver, and blood vessels from a number of malignant tumors.

13 independent risk factors in various types of malignant tumors.

14 ntibody D93/TRC093 in patients with advanced malignant tumors.

15 ization therapies in GBM, and possibly other malignant tumors.

16 l excision is one of the main treatments for malignant tumors.

17 ese progeny can dedifferentiate and generate malignant tumors.

18 unleashes the body's immune response against malignant tumors.

19 ominant disorder characterized by benign and malignant tumors.

20 Such a network has not been identified in malignant tumors.

21 e of this genetically heterogeneous group of malignant tumors.

22 and cannot reliably distinguish benign from malignant tumors.

23 he possible development of resistance to new malignant tumors.

24 estrained cell growth and chemoresistance of malignant tumors.

25 ed permeability in inflammatory diseases and malignant tumors.

26 oprotein that is highly expressed in several malignant tumors.

27 in the tumorigenesis or metastasis of other malignant tumors.

28 ial drug intervention to treat diet-enhanced malignant tumors.

29 ion, which transforms preneoplastic cells to malignant tumors.

30 on is correlated with the metastasis of some malignant tumors.

31 s for the most commonly prenatally diagnosed malignant tumors.

32 gression of prostate premalignant lesions to malignant tumors.

33 the effects of hypoxia in normal tissues and malignant tumors.

34 diseases, such as inflammatory diseases and malignant tumors.

35 ffect, are found in most if not all types of malignant tumors.

36 identified, of which 826 (0.8%) were primary malignant tumors.

37 rgeted by deletion and inactivation in human malignant tumors.

38 indispensable roles for CXCR2 in benign and malignant tumors.

39 id or fluid behavior influence the spread of malignant tumors.

40 ogression, growth, and therapy resistance of malignant tumors.

41 to be one of the most indicative markers of malignant tumors.

42 on is a potential therapeutic target in many malignant tumors.

43 bidity and mortality that is attributable to malignant tumors.

44 tudies addressing (18)F-FDG repeatability in malignant tumors.

45 rview of the current state of SBRT for solid malignant tumors.

46 adjacent tissues, suggesting that they were malignant tumors.

47 linical trials for stage 0 to IV solid organ malignant tumors.

48 ity often correlates with the progression of malignant tumors.

49 mmatory lesions and in many premalignant and malignant tumors.

50 HL disease that displays multiple benign and malignant tumors.

51 existing therapies to consistently eradicate malignant tumors.

52 rve of 0.96 for distinguishing benign versus malignant tumors.

53 etely separate clustering between benign and malignant tumors.

54 can contribute to the immune surveillance of malignant tumors.

55 oncern regarding the successful treatment of malignant tumors.

56 ivity detection and efficient elimination of malignant tumors.

57 c biomarker in differentiation of benign and malignant tumors.

58 d is under investigation for different solid malignant tumors.

59 rsus a rapid onset of symptoms in those with malignant tumors.

60 ncogene and a promising drug target in human malignant tumors.

61 ssemination and angiogenesis of KSHV-induced malignant tumors.

62 evelopment and/or progression of a number of malignant tumors.

63 oimmune and other inflammatory disorders and malignant tumors.

64 advance towards the effective eradication of malignant tumors.

65 sent more than half of LLRs are performed in malignant tumors.

66 mising treatment option for various types of malignant tumors.

67 dules should be considered in the staging of malignant tumors.

68 Forty-four of the 115 patients (38%) had malignant tumors, 42 had benign tumors (37%), and 29 (25

69 Fifty percent were for malignant tumors, 45% were for benign lesions, 1.7% were

70 study, 1,007 biopsy samples were reported as malignant tumors (719 gastric, 276 esophageal, and 12 du

71 est that 5hmdC is strongly depleted in human malignant tumors, a finding that adds another layer of c

72 is often used in progressive pediatric solid malignant tumors, a literature review reveals that only

73 ofile the genomic landscape of 42 benign and malignant tumors across 13 individuals from four multige

74 There was a 7.9% incidence of malignant tumors after a mean posttransplant follow-up o

75 barriers and promote intermediate or overtly malignant tumors along distinct progression trajectories

76 BRCA1/2 carriers may reduce lifetime risk of malignant tumor and eliminate intraperitoneal cancer.

77 ting tissue fluidity were abnormally high in malignant tumors and allowed them to be distinguished fr

78 The malignant tumors and benign lesions demonstrated differe

79 Abnormal pH is a common feature of malignant tumors and has been associated clinically with

80 ion 3 (STAT3) is constitutively activated in malignant tumors and has important roles in multiple asp

81 ted the association between TWIST1 and C3 in malignant tumors and in murine embryos.

82 such as CA IX, which has been identified in malignant tumors and is associated with extracellular ac

83 Metastasis is a defining feature of malignant tumors and is the most common cause of cancer-

84 n normal tissues, it is broadly expressed in malignant tumors and may favor tumor immune escape.

85 might also play a role in the progression of malignant tumors and metastasis.

86 Nerve fibers are known to reside within malignant tumors and the greater the neuronal density th

87 est uptake of (64)Cu-DOTA-alendronate was in malignant tumors and the lowest uptake in benign tumors

88 reas are a common feature of rapidly growing malignant tumors and their metastases and are typically

89 yes, brain, and spine, as well as benign and malignant tumors and/or cysts of the kidneys, adrenal me

90 ad familial, multiple, extra-adrenal, and/or malignant tumors and/or were younger than 40 years.

91 the effects of APN deficiency in allografted malignant (tumor) and nonmalignant (host) cells on tumor

92 tions in the same positions were reported in malignant tumors, and a de novo missense substitution in

93 16, which have been causally associated with malignant tumors, and low-risk HPVs such as HPV-11, whic

94 nsible for induction of T cell senescence by malignant tumors, and then discuss potential strategies

95 conducted per year, a significant number of malignant tumors are (18)F-FDG PET-negative.

96 Malignant tumors are caused by uncontrolled proliferatio

97 to lactate production for energy generation, malignant tumors are characterized by increased glycolys

98 Malignant tumors are common in the colon and breast but

99 Malignant tumors are considered "unresectable" if they a

100 Mounting evidence suggests that malignant tumors are initiated and maintained by a subpo

101 Cutaneous malignant tumors are the most frequent adverse events of

102 Malignant tumors are typically associated with altered r

103 Many solid malignant tumors arise on a background of inflamed and/o

104 yndrome (PHTS), featuring various benign and malignant tumors, as well as neurodevelopmental disorder

105 transplant recipients who were treated for a malignant tumor before transplantation are at an increas

106 ments, and changes in those measurements, in malignant tumors before and after therapy.

107 of screening mammography is to detect small malignant tumors before they grow large enough to cause

108 antigens are expressed in a wide variety of malignant tumors but not in adult somatic cells, renderi

109 function makes a known contribution to many malignant tumors, but the role of stem cells in benign t

110 C) accounts for several percent of all adult malignant tumor cases and is directly associated with ov

111 metastasis; however, its roles in regulating malignant tumor cell behavior remain unclear.

112 ssential roles in the development of various malignant tumor cell invasion and metastasis.

113 Transduction of the malignant tumor cell line BT549 on the other hand does n

114 vity has been widely examined in an array of malignant tumor cell types; however, very little is know

115 d in aberrant growth and survival signals in malignant tumor cells and is a validated target for anti

116 ular, are overexpressed on the glycocalyx of malignant tumor cells and sialic acid-mediated cell adhe

117 tromal interaction alters gene expression in malignant tumor cells and stromal cells creating a uniqu

118 s, these nanoparticles can be used to target malignant tumor cells and tumor microenvironments with h

119 We show that EVs released by malignant tumor cells are taken up by less malignant tum

120 inst Axl may block Axl functions not only in malignant tumor cells but also in the tumor stroma.

121 ece of heterogeneous mass including not only malignant tumor cells but also the stroma, the importanc

122 use the strain backgrounds vary, whereas the malignant tumor cells do not, any observed changes in tu

123 y malignant tumor cells are taken up by less malignant tumor cells located within the same and within

124 Restoring LIFR expression in highly malignant tumor cells suppresses metastasis by triggerin

125 Exposing rare but highly malignant tumor cells that migrate from the primary tumo

126 By intravital imaging, we show that the less malignant tumor cells that take up EVs display enhanced

127 y (BNCT) allows the selective elimination of malignant tumor cells without affecting healthy tissue.

128 It is heavily secreted by malignant tumor cells, allowing the protease to serve as

129 ion of a glioma in terms of concentration of malignant tumor cells.

130 al cells, leading to both benign (warts) and malignant tumors (cervical cancer).

131 Glioblastomas (GBMs) are malignant tumors characterized by their vascularity and

132 In a molecularly related B-cell malignant tumor (classic Hodgkin lymphoma), tumor Reed-S

133 Melanoma is a malignant tumor derived from epidermal melanocytes, and

134 ic window between normal tissue toxicity and malignant tumor destruction would still offer great valu

135 Malignant tumors develop through multiple steps of initi

136 acetylases (HDACs) have been associated with malignant tumor development and progression in humans.

137 tion of mTORC1 in normal cells could lead to malignant tumor development in several tissues.

138 200 kDa) in various tissues did not lead to malignant tumor development in vivo.

139 rpinning macrophage proliferation to support malignant tumor development, thereby strengthening the v

140 Benign and malignant tumors differ in the viscoelastic properties o

141 ations with municipal mortality due to these malignant tumors during the period 1999-2008.

142 Malignant tumors evolve through dynamic responses to mic

143 mice, spontaneously transformed cells formed malignant tumors expressing GIST markers.

144 These tumors are aggressive malignant tumors for which adjuvant modalities have not

145 t link mitochondrial Ca(2+) homeostasis with malignant tumor formation and growth remain elusive.

146 Given that no malignant tumor formation was observed even after a long

147 ility of Notch receptor paralogs to initiate malignant tumor formation, and suggest that glial precur

148 d flow cytometry that, similar to many other malignant tumors, freshly isolated myeloma cells express

149 amples spanning normal tissue and benign and malignant tumors from each patient.

150 ma requires accurate differentiation of true malignant tumors from highly atypical lesions, which lac

151 mammary tissue (normal, benign diseases, or malignant tumors) from 87 women with and without breast

152 of benign prostatic hyperplasia regions and malignant tumors, from 39 prostate cancer patients.

153 ssive glioma phenotype, along with increased malignant tumor growth and poor survival.

154 a critical functional role for fibrinogen in malignant tumor growth.

155 whether and how bacterial sepsis may impact malignant tumor growth.

156 associated with infectious mononucleosis and malignant tumors, harbors many immune-evasion proteins t

157 Most malignant tumors have elevated levels of Tn, an O-GalNAc

158 These highly malignant tumors have increased activation of the phosph

159 recent clinical results showing that highly malignant tumors have lost the ability to accumulate nCL

160 at is critical for suppressing the growth of malignant tumors; however, the mechanisms allowing ITGA7

161 ancer (CaP) is the most frequently diagnosed malignant tumor in American men, the mechanisms underlyi

162 NBL, the most common extracranial solid malignant tumor in children, covers a wide spectrum of t

163 rs (ECs) are one of the most common types of malignant tumor in females.

164 Neuroblastoma is the most common malignant tumor in infants, and in young infants, 90% of

165 significant substantial risk of a secondary malignant tumor in patients who do not succumb to metast

166 Osteosarcoma is a malignant tumor in the bone, which originates from norma

167 hepatic cholangiocarcinoma (ICC) is a severe malignant tumor in which the standard therapies are most

168 ahepatic cholangiocarcinoma (ICC) is asevere malignant tumor in which the standard therapies are most

169 We observed spontaneous malignant tumors in 54 of 93 Bap1-mutant mice (58%) vers

170 he anaphylatoxin C5a, promotes the growth of malignant tumors in a mouse model of cervical carcinoma.

171 ses that are associated with both benign and malignant tumors in animals and humans.

172 h Pten loss (Pten(IEKO);Tgfbr2(IEKO)) led to malignant tumors in both the small intestine and colon i

173 aviridae that are associated with benign and malignant tumors in humans and animals.

174 nfertility, neurodegenerative disorders, and malignant tumors in humans.

175 gnant) and standardized incidence ratios for malignant tumors in individuals with DICER1 pathogenic v

176 rostate cancer (PCA), one of the most common malignant tumors in men, is the second leading cause of

177 ghly proliferative and poorly differentiated malignant tumors in mice.

178 t that PTEN may safeguard against developing malignant tumors in patients with TSC deficiency.

179 distal pancreatectomy for benign or lowgrade malignant tumors in the body/tail of the pancreas were i

180 istal pancreatectomy for benign or low-grade malignant tumors in the body/tail of the pancreas.

181 Glioma accounts for 80% of all primary malignant tumors in the central nervous system, and thes

182 Malignant tumors included melanoma (12%), squamous cell

183 The few malignant tumors included melanoma and lymphoma.

184 n Hippel-Lindau (VHL) can lead to benign and malignant tumors, including clear-cell renal cell carcin

185 2 (HMGA2) is found in a number of benign and malignant tumors, including the clonal PIGA(-) cells in

186 be upregulated or activated in a variety of malignant tumors, including those from thyroid, colon an

187 ssociated with the expansion of rare, highly malignant tumor-initiating stem cells (TISCs) through po

188 s support the inappropriate growth of intact malignant tumors is incompletely understood.

189 could explain these BRAF wild-type secondary malignant tumors is still unknown.

190 nd (6) A375P-cells were derived from a solid malignant tumor located in the lung.

191 performed more frequently, even for larger, malignant tumors located in challenging locations.

192 Certain malignant tumors may also depend on cellular hierarchies

193 haracteristics that differentiate benign and malignant tumors may inform our understanding of the mal

194 Malignant tumors metabolize glucose to lactate even in t

195 ibroblasts that suggest the development of a malignant tumor microenvironment.

196 Thus, targeting tissue fluidity of malignant tumors might open horizons for the diagnosis a

197 viduals and patients with different types of malignant tumors, mostly carcinomas, where the increased

198 ses: fibroma (n = 30), rhabdomyoma (n = 14), malignant tumor (n = 12), hemangioma (n = 9), thrombus (

199 18) or liver (n = 12) resection, mainly for malignant tumors (n = 29).

200 All malignant tumors (n = 32) were hypermutant.

201 Malignant tumors negatively affect early and late surviv

202 ith no liver disease who had surgery for non malignant tumor (normal hepatocytes).

203 Gastric cancer (GC), an aggressive malignant tumor of the alimentary tract, is a leading ca

204 a (PLGA) is the second most frequent type of malignant tumor of the minor salivary glands.

205 In 26 malignant tumors of 0.6-2.5 cm in size, Hb(T) was signif

206 Liposarcomas are rare malignant tumors of adipocytic differentiation.

207 Malignant tumors of adrenal glands should be taken into

208 a critical cellular event for metastasis of malignant tumors of epithelium origin.

209 genetic disorder characterized by benign and malignant tumors of neural crest origin.

210 arcoma family of tumors (ESFT) is a group of malignant tumors of soft tissue and bone sharing a chrom

211 Malignant tumors of the central nervous system (CNS) con

212 positive and negative predictive values for malignant tumors of the conjunctiva and eyelid margin we

213 examination conducted with the slitlamp for malignant tumors of the eyelid margin (98% vs 92%) and c

214 perative strategy for oncologic resection of malignant tumors of the liver and an optimal postoperati

215 Recommendations for resection of malignant tumors of the liver based on traditional consi

216 The operative strategy for resection of malignant tumors of the liver should address the key com

217 man papillomaviruses (HPVs) cause benign and malignant tumors of the mucosal and cutaneous epithelium

218 s are prone to the development of benign and malignant tumors of the nervous system.

219 TKTL1 is dysregulated in malignant tumors of the ocular adnexa, and enhanced expr

220 euroendocrine tumors (NETs) are uncommon but malignant tumors of the thymus gland that are usually as

221 less, mutant p53 mice are viable and develop malignant tumors only on adulthood.

222 ancer research to date have focused on fully malignant tumors or cancer cell lines, but the potential

223 e the mediastinum (group C, n=16), and other malignant tumors outside the thymus (group D, n=38).

224 11 years for benign tumors and 14 years for malignant tumors (P = .005), with mean difference of 3 y

225 sion correlated with the patient outcomes in malignant tumors (P = 0.045).

226 ith benign lesions vs 18 of 44 patients with malignant tumors [P < .001]), and internal vascularizati

227 ith benign lesions vs 22 of 44 patients with malignant tumors [P < .001]), irregular margins (26 of 8

228 ith benign lesions vs 42 of 44 patients with malignant tumors [P < .001]).

229 lead to genomic instability and ultimately a malignant tumor phenotype.

230 stance to therapy, poorer survival, and more malignant tumor phenotypes.

231 We also identified six genes driving malignant tumor progression and a new human CRC tumor-su

232 es-9 (MMP-9), which has been associated with malignant tumor progression and metastasis by matrix deg

233 elial-mesenchymal transition (EMT) underlies malignant tumor progression and metastatic spread by ena

234 xpressed in cancer cells and associated with malignant tumor progression and poor outcome.

235 data indicate that RES suppresses UV-induced malignant tumor progression in p53(+/-)/SKH-1 mice and t

236 In animal models, repeated exertion reduces malignant tumor progression, and clinically, exercise ca

237 a play a central and multifunctional role in malignant tumor progression, and targeting mitochondria

238 in tumor microenvironment may contribute to malignant tumor progression.

239 or microenvironment has significant roles in malignant tumor progression.

240 like features, and ultimately contributes to malignant tumor progression.

241 ation has been recognized as one hallmark of malignant tumor progression.

242 function (haploinsufficiency) fosters benign malignant tumor progression.

243 ta, whose activities are dysregulated during malignant tumor progression.

244 he local tissue microenvironment may enhance malignant tumor progression.

245 e fibroblasts to express genes that promoted malignant tumor progression; indeed, treatment with reco

246 The finding suggests that malignant tumors promote invasion/metastasis not only th

247 Malignant tumors release growth factors such as VEGF-C t

248 ogic settings including retinal ischemia and malignant tumors, robust angiogenesis occurs despite the

249 Malignant tumors secrete large numbers of extracellular

250 However, some malignant tumors show a paucity of chromosomal alteratio

251 morphologic and kinetic features of various malignant tumor subtypes and benign diseases, either vis

252 cancer, as well as multiple blood cell-based malignant tumors, such as lymphoma.

253 The growth and spread of malignant tumors, such as ovarian carcinomas, are govern

254 based on diagnostics imaging between MO and malignant tumors, such as parosteal sarcoma, synovial sa

255 In conclusion, although malignant tumors tend to exhibit increased rigidity, int

256 Malignant tumors tend to occur in older patients and dem

257 inoma (ccRCC) is a common aggressive urinary malignant tumor that cannot be easily diagnosed at an ea

258 ous cell carcinoma (OSCC) is the most common malignant tumor that occurs in the oral mucosa.

259 Retinoblastoma is a highly invasive malignant tumor that often invades the brain and metasta

260 s potentially applicable to several types of malignant tumors that demonstrate chemoresistance and ma

261 Eighty percent of malignant tumors that develop in the central nervous sys

262 nchymal GBM subtype in particular are highly malignant tumors that frequently exhibit regions of seve

263 primary extracranial, nonhematopoietic solid malignant tumors that progress after at least 2 lines of

264 primary extracranial, nonhematopoietic solid malignant tumors that progressed after at least 2 lines

265 ically and clinically heterogeneous group of malignant tumors that resemble developing skeletal muscl

266 ability in this system, a novel approach for malignant tumor therapy is demonstrated.

267 the acidic extracellular microenvironment of malignant tumor tissue.

268 by biopsy), size, and TNM Classification of Malignant Tumors (TNM).

269 yed (18)F-FDG PET imaging typically enhances malignant tumor to background.

270 inct from exhaustion, a key strategy used by malignant tumors to evade immune surveillance and sustai

271 or effect primarily in cells originated from malignant tumors: transformed cell line of non-cancer or

272 lls, the prevalence and growth of benign and malignant tumors, treatment effectiveness and costs, and

273 AP1 are predisposed to a range of benign and malignant tumor types, including malignant mesothelioma,

274 of infected individuals develop a subsequent malignant tumor, underscoring the important role that ho

275 However, malignant tumors underwent lower mean HMI displacement (

276 These cells formed malignant tumors upon s.c. injection into immunocompromi

277 0.0001) in discriminating between benign and malignant tumors using logistic regression method regard

278 patterns and biological pathways specific to malignant tumors versus those arising in benign tumors o

279 SUVmax of the benign and malignant tumors was compared.

280 Patients >/= 70 years old with a malignant tumor were included if a new cancer event occu

281 Forty-eight patients with 51 malignant tumors were assessed.

282 Features of benign and malignant tumors were compared.

283 erative factors of patients with and without malignant tumors were compared.

284 Ten dogs with biopsy-verified spontaneous malignant tumors were included for imaging.

285 rsus nonneoplastic lesions and benign versus malignant tumors were parenchymal microlithiasis (26 of

286 Malignant tumors were seen only in adolescent boys.

287 bnormalities even at early passages and form malignant tumors when transplanted in vivo.

288 of immune evasion in chronic infections and malignant tumors will continue to help in the goal of op

289 rcinoma (SDC) is an uncommon, but aggressive malignant tumor with a high mortality rate.

290 Human uveal melanoma (UM) is a major ocular malignant tumor with high risk of metastasis and require

291 c alterations, resulting in the formation of malignant tumors with aggressive local invasion and epit

292 cinoma (cSCC) is one of the most common skin malignant tumors with an increasing incidence.

293 Malignant tumors with deregulated FGF-2 expression such

294 mising option for differentiation therapy in malignant tumors with dysregulated HDAC3 activity.

295 , most PinX1+/- mice spontaneously developed malignant tumors with evidence of chromosome instability

296 mas occurring at transition zones are highly malignant tumors with poor prognosis.

297 Vascular leiomyosarcomas are aggressive malignant tumors, with high recurrence rates.

298 14 teratomas) generated major dysplasia and malignant tumors, with yolk sac tumors and embryonal car

299 ar carcinoma (HCC) is one of the most common malignant tumors worldwide and is almost uniformly fatal

300 nd breast cancers (TC, BC) are common female malignant tumors worldwide.